Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.
Latest from Andrew McConaghie
The changes expand the commercial potential of the PD-1/VEGF targeting immunotherapy's trial, but worries about delays and endpoint success have reigned in Summit's formerly skyrocketing share price.
Sales of Arexvy fell back in the third quarter but GSK’s leadership believes the vaccine and several pipeline drugs can help the company achieve higher growth.
It is chasing Summit and other companies in the PD1/VEGF field, but Ottimo’s CEO David Epstein believes it has a unique drug design – plus a clear plan for a big pharma buyout
Breaking with convention, Thomas Schinecker has said allowing the $16.5bn acquisition to go ahead would be “the wrong decision”. Novo Nordisk says otherwise.
Potential blockbusters in the Alzheimer’s, Parkinson’s and lung cancer fields will produce much-awaited results this quarter, as the Swiss major reported solid Q3 growth.
Response Pharma aims to help people transition off Wegovy and Zepbound and maintain weight their loss in the long-term – making it one of many biopharma companies looking to fill gaps in the growing obesity segment.